NXTC vs. KZR, HOOK, PRTK, ABEO, ALIM, RIGL, VERU, SGMT, CNTX, and RNAC
Should you be buying NextCure stock or one of its competitors? The main competitors of NextCure include Kezar Life Sciences (KZR), Hookipa Pharma (HOOK), Paratek Pharmaceuticals (PRTK), Abeona Therapeutics (ABEO), Alimera Sciences (ALIM), Rigel Pharmaceuticals (RIGL), Veru (VERU), Sagimet Biosciences (SGMT), Context Therapeutics (CNTX), and Cartesian Therapeutics (RNAC). These companies are all part of the "medical" sector.
NextCure (NASDAQ:NXTC) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, community ranking, profitability, valuation and dividends.
Kezar Life Sciences received 56 more outperform votes than NextCure when rated by MarketBeat users. However, 63.93% of users gave NextCure an outperform vote while only 58.01% of users gave Kezar Life Sciences an outperform vote.
42.7% of NextCure shares are owned by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are owned by institutional investors. 13.3% of NextCure shares are owned by insiders. Comparatively, 9.3% of Kezar Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Kezar Life Sciences' return on equity of -47.28% beat NextCure's return on equity.
NextCure has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.
In the previous week, NextCure had 4 more articles in the media than Kezar Life Sciences. MarketBeat recorded 6 mentions for NextCure and 2 mentions for Kezar Life Sciences. Kezar Life Sciences' average media sentiment score of 0.94 beat NextCure's score of 0.48 indicating that Kezar Life Sciences is being referred to more favorably in the news media.
NextCure has higher earnings, but lower revenue than Kezar Life Sciences. NextCure is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.
NextCure presently has a consensus target price of $6.00, suggesting a potential upside of 289.61%. Kezar Life Sciences has a consensus target price of $11.00, suggesting a potential upside of 1,485.01%. Given Kezar Life Sciences' higher possible upside, analysts clearly believe Kezar Life Sciences is more favorable than NextCure.
Summary
Kezar Life Sciences beats NextCure on 9 of the 16 factors compared between the two stocks.
Get NextCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NextCure Competitors List
Related Companies and Tools
